Oral therapy for erectile dysfunction with type-5 phosphodiesterase (PDE5) inhibitors has revolutionized treatment. This review presents a comprehensive update on PDE5 inhibitors and covers areas including erectile physiology, pharmacology, dosing and side effects. In addition, the use of these drugs in certain clinical situations including cardiovascular disease, as well as a discussion of rare adverse events, daily dosing, use of these drugs for the treatment of lower urinary tract systems, recreational use, novel uses for PDE5 inhibitors, and strategies for treatment failures are covered in detail. Because of the widespread use of PDE5 inhibitors for the treatment of erectile dysfunction, a comprehensive under-standing of these issues by health-care providers is necessary to ensure safe and effective prescribing practices and to improve patient satisfaction and quality of life.

The objective of this study is to report the initial results of a newly established robotic prostatectomy (DVP) program at a Veteran's Affairs (VA) medical center. All patients who underwent a radical prostatectomy during the first 18 months of our robotic surgical program were included in this study. These patients were compared to a control group that included all patients who underwent an open prostatectomy 18 months prior to starting our robotic program. Preoperative, intraoperative and postoperative data was compared between open and robotic prostatectomies. 38 men underwent radical retropubic prostatectomy (RRP) between September 2007 and February 2009. With the introduction of robotic prostatectomy, the total number of prostatectomies increased by 84 % to 70 (9 RRP, 61 DVP). Prostate-specific antigen (PSA), Gleason score and clinical stage were similar for both groups. Average estimated blood loss (EBL) was 1205 mL for RRP and 126 mL for DVP. Mean operative times in minutes were 259 and 254 for RRP and DVP, respectively. Complications included two rectal perforations, a cerebrovascular accident, one death after RRP and one open conversion for failure to progress. Average length of stay was 5.1 for RRP and 1.8 days for DVP. Total positive margins were 24 % for RRP and 15 % for DVP. For T2-specific disease, 16.7 % had positive margins after RRP compared to 4.3 % after DVP. The establishment of a robotic prostatectomy program at a tertiary VA medical center was achieved in a safe and efficient manner with improvement in EBL and length of stay when compared to our open prostatectomies. Oncologic outcomes were equivalent when compared to other initial DVP programs.

No abstract

No abstract